- Shattuck Labs Inc STTK announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including data from SL-9258 (TIGIT-Fc-LIGHT) and the Company's GADLEN platform.
- Preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a bispecific fusion protein from its ARC platform, demonstrates that SL-9258 simultaneously provides checkpoint blockade to all tumor-expressed PVR ligands and broadens immune costimulation.
- TIGIT-Fc-LIGHT was evaluated and well-tolerated in non-human primates at doses up to 40 mg/kg, and similar on-target pharmacodynamic activity was observed to what was characterized preclinically in mice.
- Related: Takeda, Shattuck Labs Terminate Immuno-Oncology Pact.
- Shattuck presented preclinical data highlighting the potential of GADLENs to direct gamma delta T cells to kill tumor cells.
- Shattuck's bispecific GADLENs, targeting CD19 or CD20 tumor-antigens, demonstrated an ability to induce proliferation, degranulation, and cytokine production in Vg9Vd2+ T cells with costimulation of a natural cytotoxicity receptor or T cell costimulatory receptor.
- Further, CD19 and CD20 directed GADLENs enhanced the specific killing of lymphoma cells that express both antigen targets.
- Price Action: STTK shares are down 2.79% at $3.83 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in